Organon 2025 Q1 Earnings Misses Targets as Net Income Falls 56.7%
Friday, May 2, 2025 5:18 am ET
55min read Organon (OGN) reported its fiscal 2025 Q1 earnings on May 01st, 2025. The company missed expectations as total revenue decreased by 6.7% to $1.51 billion, and net income fell 56.7% to $87 million. organon reaffirmed its 2025 revenue and adjusted EBITDA margin guidance, targeting over $900 million in free cash flow. The company aims to maintain a net leverage ratio below 4 by year-end, despite challenges from the loss of exclusivity of Atozet.
Revenue
Organon's total revenue for Q1 2025 was $1.51 billion, reflecting a 6.7% decrease from the previous year. The Women’s Health segment accounted for $463 million, while Established Brands generated $887 million. The Biosimilars segment saw revenue of $141 million, and the Cardiovascular and Respiratory segments contributed $274 million and $236 million, respectively. Non-Opioid Pain, Bone and Dermatology brought in $217 million, while Other segments added $182 million.
Earnings/Net Income
Organon's EPS dropped 56.4% to $0.34 in Q1 2025 from $0.78 in Q1 2024, with net income also declining 56.7% to $87 million. The earnings figures indicate a challenging quarter for the company, reflecting a significant decrease in profitability.
Post-Earnings Price Action Review
Following the release of its earnings report, Organon's stock experienced notable volatility. Historical data suggests that the company's earnings metrics, including revenue, net income, and EPS, have led to medium-term positive returns in the past. The 30-day win rate for each metric stands at 51.00%, indicating a tendency toward positive price momentum over a month. However, short-term fluctuations are common, as seen by the mixed win rates over shorter periods. Despite recent declines, the potential for positive returns remains, with a maximum observed return of 11.40% occurring 79 days post-report. Investors are advised to consider these patterns alongside other factors when evaluating the stock's future performance.
CEO Commentary
Kevin Ali, CEO of Organon, expressed optimism regarding the company’s performance, noting a solid start to 2025 with key growth drivers like Nexplanon on track. He highlighted successful product launches and the company's limited exposure to tariffs. Ali emphasized a focus on deleveraging and strengthening future prospects through business development and a leaner cost structure.
Guidance
Organon affirmed its revenue and adjusted EBITDA margin guidance for 2025, targeting over $900 million in free cash flow before one-time costs. The company expects significant contributions from Nexplanon and Vtama, with Vtama projected to achieve $150 million in revenue this year. Organon remains committed to maintaining a net leverage ratio below 4 by year-end, anticipating growth despite challenges from Atozet's loss of exclusivity.
Additional News
Organon recently appointed Ramona A. Sequeira to its Board of Directors, bringing extensive industry experience. The company also announced the acquisition of TOFIDENCE™, a biosimilar to ACTEMRA® for intravenous infusion in the U.S., enhancing its biosimilars portfolio. Furthermore, Organon reset its capital allocation priorities, reducing its dividend to $0.08 per share to accelerate deleveraging efforts. These strategic moves reflect Organon's focus on strengthening its financial position and expanding its market presence.
Revenue
Organon's total revenue for Q1 2025 was $1.51 billion, reflecting a 6.7% decrease from the previous year. The Women’s Health segment accounted for $463 million, while Established Brands generated $887 million. The Biosimilars segment saw revenue of $141 million, and the Cardiovascular and Respiratory segments contributed $274 million and $236 million, respectively. Non-Opioid Pain, Bone and Dermatology brought in $217 million, while Other segments added $182 million.
Earnings/Net Income
Organon's EPS dropped 56.4% to $0.34 in Q1 2025 from $0.78 in Q1 2024, with net income also declining 56.7% to $87 million. The earnings figures indicate a challenging quarter for the company, reflecting a significant decrease in profitability.
Post-Earnings Price Action Review
Following the release of its earnings report, Organon's stock experienced notable volatility. Historical data suggests that the company's earnings metrics, including revenue, net income, and EPS, have led to medium-term positive returns in the past. The 30-day win rate for each metric stands at 51.00%, indicating a tendency toward positive price momentum over a month. However, short-term fluctuations are common, as seen by the mixed win rates over shorter periods. Despite recent declines, the potential for positive returns remains, with a maximum observed return of 11.40% occurring 79 days post-report. Investors are advised to consider these patterns alongside other factors when evaluating the stock's future performance.
CEO Commentary
Kevin Ali, CEO of Organon, expressed optimism regarding the company’s performance, noting a solid start to 2025 with key growth drivers like Nexplanon on track. He highlighted successful product launches and the company's limited exposure to tariffs. Ali emphasized a focus on deleveraging and strengthening future prospects through business development and a leaner cost structure.
Guidance
Organon affirmed its revenue and adjusted EBITDA margin guidance for 2025, targeting over $900 million in free cash flow before one-time costs. The company expects significant contributions from Nexplanon and Vtama, with Vtama projected to achieve $150 million in revenue this year. Organon remains committed to maintaining a net leverage ratio below 4 by year-end, anticipating growth despite challenges from Atozet's loss of exclusivity.
Additional News
Organon recently appointed Ramona A. Sequeira to its Board of Directors, bringing extensive industry experience. The company also announced the acquisition of TOFIDENCE™, a biosimilar to ACTEMRA® for intravenous infusion in the U.S., enhancing its biosimilars portfolio. Furthermore, Organon reset its capital allocation priorities, reducing its dividend to $0.08 per share to accelerate deleveraging efforts. These strategic moves reflect Organon's focus on strengthening its financial position and expanding its market presence.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
